Umibe, thank you for reminding me that Dr. Stupp stated that he could not rely on the long term survival results of the Optune arm because those patients were not followed for a long enough period of time. Now even if the 5 year survival of the Optune and DCVax-L trials had very similar OS results for the respective treatment arms, it is highly unlikely that the spectacular results of the DCVax-L trial's crossover group can be matched by the helmet or for that matter, any other treatment. Furthermore, I know of no potential adjuvants for the helmet whereas there is already plenty of evidence that treatments that can potentiate the immunotherapeutic effects of DCVax-L, would further increase the lifespan of GBM patients.
As for quality of life, If I were a GBM patient, I would certainly prefer the DCVax-L treatments with their non existent side effects to wearing the helmet for 18 hours every day.
News 
Market Data 
Discover 
